Heron Therapeutics, Inc.
HRTXHeron Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies primarily in the areas of oncology and acute care. The company’s portfolio includes drugs designed to manage pain and other symptoms associated with cancer treatment and surgical procedures. Heron aims to improve patient outcomes through targeted, novel formulations and delivery methods.
Company News
Heron Therapeutics announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025. Cusack brings over 20 years of investment management and corporate finance experience, most recently serving as a Managing Director at Starboard Value LP.
Heron Therapeutics, a commercial-stage biotechnology company, will host a conference call on November 12, 2024, to report its third quarter 2024 financial results and discuss recent business highlights.
The global chemotherapy-induced nausea and vomiting treatment market is expected to grow at a CAGR of 6.4% and reach a valuation of US$ 12,688.0 million by 2034, driven by the increasing incidence of cancer and the need for effective management of CINV.
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
